New PARP Inhibitor Approved for Breast Cancer
The FDA approval of talazoparib means there are now two PARP inhibitors that can be used to treat patients...
Linking Adolescent and Early Adulthood Diet to Breast Cancer Risk
A new study suggests that diet during adolescence and early adulthood may be associated with premenopausal breast cancer risk....
Affordable Care Act Increased Access to Breast Cancer Care
The number of Hispanic breast cancer patients getting care and participating in a clinical trial in a cancer center...
Treating Triple-negative Breast Cancer with Immunotherapy
The U.S. FDA approved the immune checkpoint inhibitor pembrolizumab combined with chemotherapy to treat certain breast cancer patients before...
A New Cancer Inhibitor and Diagnostic Test for Early, High-risk Breast Cancer
THE FDA APPROVED A NEW TYPE OF CANCER INHIBITOR FOR CERTAIN PATIENTS WITH A HIGH RISK OF RECURRENCE The...
A New Treatment Option for the Most Common Type of Breast Cancer
A drug that selectively targets cancer cells was approved for the treatment of certain HR-positive breast cancers. The U.S....
A New First-line Option for Metastatic Breast Cancer
Fam-trastuzumab deruxtecan-nxki (T-DXd) with pertuzumab was approved to treat metastatic HER2-positive breast cancer. The U.S. Food and Drug Administration...
First Approval for New Antibody-drug Conjugate in Breast Cancer
The FDA has issued its first approval for datopotamab deruxtecan-dlnk, a targeted therapy, for certain types of breast cancer. ...
Expanding Treatment Options for Aggressive Breast Cancer
The FDA approved the use of an immunotherapeutic in combination with chemotherapy to treat certain patients with triple-negative breast...
A New Molecularly Targeted Therapeutic for Breast Cancer
The FDA has approved a new molecularly targeted therapeutic to treat breast cancer patients with a specific subtype of...
PARP Inhibitor Approved as Adjuvant Treatment for High-risk, Early Breast Cancer
The FDA approved olaparib for patients with breast cancer who have inherited BRCA mutations and have received prior neoadjuvant...
Targeting HER2-positive Metastatic Breast Cancer
The FDA has expanded the use of the molecularly targeted therapeutic neratinib to include the treatment of certain patients...
New Targeted Therapy for Hormone Receptor-positive Breast Cancer
The FDA has approved capivasertib for the treatment of breast cancers with certain mutations. The U.S. Food and Drug...
Targeting Breast Cancer
The molecularly targeted therapeutic alpelisib was approved for certain patients who have advanced or metastatic breast cancer. The U.S....
Expanded Indication for a Targeted Therapy for Early Breast Cancer
The FDA approved abemaciclib with endocrine therapy for HR-positive, HER2-negative, early-stage breast cancer at high risk of recurrence. The...
Low-Fat Diet Can Improve Outcomes for Breast Cancer Patients
Lowering dietary fat intake reduced death rates in a subgroup of women with breast cancer who were part of...
First Biosimilar for Pertuzumab Approved for HER2-positive Breast Cancer
The FDA approved pertuzumab-dpzb for interchangeable use with pertuzumab. The U.S. Food and Drug Administration (FDA) has approved pertuzumab-dpzb...
A New Option for Breast Cancer Patients
The FDA approved a HER2-targeted therapy for the treatment of breast tumors with low HER2 expression. The U.S. Food...
New Oral SERD Approved for Certain Estrogen Receptor-mutated Breast Cancers
The FDA has approved imlunestrant for certain patients with advanced ESR1-mutated breast cancer that has progressed following previous endocrine...
Targeting Advanced Breast Cancer
The FDA approved a molecularly targeted therapeutic for postmenopausal women with HR-positive, HER2-negative breast cancer. The U.S. Food and...
A New Treatment Option for HER2-Positive Breast Cancer
The FDA has approved a new molecularly targeted therapeutic for treating certain patients with advanced or metastatic HER2-positive breast...
New Estrogen Receptor-targeting Therapy for Breast Cancer
The FDA has approved the oral SERD elacestrant to treat certain patients with estrogen receptor-positive breast cancer. The U.S....
Learn About the Latest Therapeutic Advance for Breast Cancer
Trial data first presented at the AACR Annual Meeting 2014, showed new drug doubled progression-free survival for a certain...
Examining the Impact of Alcohol Consumption and Cancer Risk
A study connects alcohol consumption with an increased risk of most types of breast cancer among African-American women. For...
Identifying Patients at Risk for Life-threatening Adverse Effect of Chemotherapy
A new genetic biomarker identified breast cancer patients at increased risk for heart damage caused by anthracycline chemotherapy. Women...
Radiation Treatment for Childhood or Young Adult Primary Cancer Linked to Worse Breast Cancer-specific Survival In Premenopausal Women
PHILADELPHIA – Among premenopausal women with breast cancer, those who were previously treated with radiation for a primary childhood,...
Award Recipients Announced for the 2022 San Antonio Breast Cancer Symposium
SAN ANTONIO – The San Antonio Breast Cancer Symposium (SABCS) and the American Association for Cancer Research (AACR), an...
Breast Cancer Patients Who Interrupted Endocrine Therapy to Pursue Pregnancy Did Not Experience Worse Short-term Recurrence Rates
Most were able to conceive and more than 60 percent gave birth SAN ANTONIO – Breast cancer patients who...
Women Carrying Rare Breast Cancer Variants Are More Likely to Develop Interval Breast Cancers
Interval cancers are often more aggressive and lethal than mammography-detected cancers PHILADELPHIA – While the presence of common breast...
Award Recipients Announced for the 2023 San Antonio Breast Cancer Symposium
SAN ANTONIO – The San Antonio Breast Cancer Symposium (SABCS) and the American Association for Cancer Research (AACR), an...